Show
Sort by
-
First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation
-
- Conference Paper
- C3
- open access
KEYNOTE-B79 phase 1b trial to evaluate the allogeneic CAR T-cells CYAD-101 and pembrolizumab in refractory metastatic colorectal cancer patients
-
- Journal Article
- A1
- open access
Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation
-
- Journal Article
- A2
- open access
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer
-
Phase I dose escalation study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1 in solid tumors
-
- Journal Article
- A1
- open access
Chimeric antigen receptor-T cells for targeting solid tumors : current challenges and existing strategies
-
Phase I open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer
-
- Journal Article
- A1
- open access
The mTOR and PP2A pathways regulate PHD2 phosphorylation to fine-tune HIF1α levels and colorectal cancer cell survival under hypoxia
-
- Journal Article
- A1
- open access
Cancer risk in immune-mediated inflammatory diseases (IMID)
-
Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients